Results 221 to 230 of about 21,331 (238)

The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review

European Journal of Medicinal Chemistry, 2018
Chengyuan Liang, Minhang Xin, Suresh Thareja   +2 more
exaly  

Bruton’s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)

Expert Opinion on Therapeutic Patents, 2019
Chengyuan Liang, Minhang Xin
exaly  

New Btk inhibitor holds promise

Nature Chemical Biology, 2010
openaire   +1 more source

A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors

Ca-A Cancer Journal for Clinicians
Chadi Hage Chehade, Georges Gebrael, Nicolas Sayegh   +2 more
exaly  

Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer

Ca-A Cancer Journal for Clinicians, 2005
Ruth M O'regan
exaly  

Was tun bei BTK-Inhibitor-Resistenz?

InFo Hämatologie + Onkologie, 2023
openaire   +1 more source

Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia

Nature Reviews Clinical Oncology
Michele Stanchina, Skye Montoya, Alvaro J Alencar   +2 more
exaly  

Besseres PFS mit neuem BTK-Inhibitor

InFo Hämatologie + Onkologie, 2023
openaire   +1 more source

Managing BTK Inhibitor-Refractory CLL

Clinical Lymphoma Myeloma and Leukemia, 2017
openaire   +1 more source

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Science
Skye Montoya, Jessie Bourcier, Meghan Thompson   +2 more
exaly